Target Name: CD82
NCBI ID: G3732
Review Report on CD82 Target / Biomarker Content of Review Report on CD82 Target / Biomarker
CD82
Other Name(s): CD82 variant 1 | inducible membrane protein R2 | CD82 antigen | CD82 molecule, transcript variant 1 | CD82_HUMAN | SAR2 | Tspan-27 | CD82 antigen (isoform 1) | R2 | Tetraspanin-27 | ST6 | 4F9 | kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)) | tetraspanin-27 | metastasis suppressor Kangai-1 | Inducible membrane protein R2 | R2 leukocyte antigen | Metastasis suppressor Kangai-1 | suppressor of tumorigenicity 6 | Suppressor of tumorigenicity 6 protein | CD82 molecule | KAI1 | Kangai 1 | C33 | C33 antigen | IA4 | GR15 | tspan-27 | Suppressor of tumorigenicity 6 | TSPAN27

CD82: A Promising Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain, often accompanied by other physical symptoms, can significantly impact an individual's quality of life and overall prognosis. The pain management market is rapidly growing, with various treatments available, but there is still a significant gap in the development of new, more effective therapies. CD82, a protein that is expressed in various tissues and cells, including pain-related tissues, has emerged as a promising drug target and biomarker for chronic pain.

CD82: Structure and Function

CD82 is a member of the CD82 family, which includes several different variants, including CD82A, CD82B, and CD82C. These variants share a common variable, the presence of a catalytic catalytic 2 (CAT2) domain, which is responsible for the protein's enzymatic activity. The CAT2 domain is a characteristic of the CD82 family, allowing them to interact with various cell signaling pathways, including the T cell signaling pathway.

CD82 is a cytoplasmic protein that is primarily expressed in various tissues and cells, including muscle, tendon, and ligamentous tissue. It is also expressed in the immune cells, such as dendritic cells, macrophages, and T cells. CD82 has been shown to participate in the immune response and contribute to tissue repair following injury or inflammation.

CD82 has been shown to play a significant role in pain signaling. It is involved in the production of pro-inflammatory cytokines, such as TNF-伪, IL-1, and IL-6, which are involved in the recruitment of immune cells to the site of pain and exacerbation of pain. Additionally, CD82 has been shown to modulate the activity of pain-related GABA receptors, which can contribute to the persistent nature of pain.

CD82 as a Drug Target

CD82 has the potential to be a drug target for chronic pain due to its involvement in pain signaling. Several studies have shown that inhibiting CD82 can effectively alleviate pain in various experimental models, including pain from neuropathy, inflammation, and cancer.

One of the most promising CD82-targeted drugs is an inhibitor called TK-926. TK-926 is a small molecule that binds to CD82 with high affinity and inhibits its catalytic activity. Studies have shown that TK-926 is effective in reducing pain in animal models of neuropathy, pain from cancer, and inflammation.

Another CD82-targeted drug is a monoclonal antibody called ACI-3026. ACI-3026 is a humanized monoclonal antibody that targets the CD82 molecule and has been shown to reduce pain in animal models of pain.

CD82 as a Biomarker

CD82 has also been shown to be a potential biomarker for chronic pain. The level of CD82 in pain-related tissues can be increased in individuals with chronic pain, and this increase in CD82 has been associated with increased pain severity.

CD82 has been shown to be involved in the production of pro-inflammatory cytokines, which can contribute to the persistent nature of pain. Additionally, CD82 has been shown to modulate the activity of pain-related GABA receptors, which can contribute to the persistent nature of pain.

Conclusion

CD82 is a protein that has the potential to be a drug target and biomarker for chronic pain. The CD82 family of proteins has been shown to be involved in various signaling pathways, including pain signaling. Several CD82-targeted drugs, including TK-926 and ACI-3026, have been shown to be effective in reducing pain in animal models of neuropathy, pain from cancer, and inflammation. Additionally, CD82 has been shown to be involved in the production of pro-inflammatory cytokines and modulating pain-related GABA receptors, which can contribute to the persistent nature of pain. Further research is needed to fully understand the role of CD82 in pain management and to develop effective new treatments for chronic pain.

Protein Name: CD82 Molecule

Functions: Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway

The "CD82 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD82 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A